ReviewRheumatology (Oxford, England)2019
Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors.
Review in Rheumatology (Oxford, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Risk factors and diagnostic biomarkers for asymptomatic immune checkpoint inhibitor-related myocarditis in patients with esophageal cancer after immunotherapy.World journal of gastroenterology · 2025Article
- Review of T Helper 2-Type Inflammatory Diseases Following Immune Checkpoint Inhibitor Treatment.Biomedicines · 2024Review
- Pathogenesis, pathological characteristics and individualized therapy for immune-related adverse effects.Chinese medical journal pulmonary and critical care medicine · 2023Review
- Article
- Outcomes of immunotherapy-related hepatotoxicity from a multi-disciplinary toxicity team.Journal of cancer research and clinical oncology · 2023Article
- Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies.Frontiers in immunology · 2023Review
- Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events.Frontiers in immunology · 2023Article
- Utilizing Biologics in Drug Desensitization.Current allergy and asthma reports · 2023Review
- Article
- Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologists' Perspectives.Middle East journal of digestive diseases · 2022Review
- Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis.Journal for immunotherapy of cancer · 2022Article
- Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment.Respiratory medicine case reports · 2022Article
- The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity.Frontiers in medicine · 2022Review
- Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment.Respiratory medicine case reports · 2022Article
- Urinary T cells are detected in patients with immune checkpoint inhibitor-associated immune nephritis that are clonotypically identical to kidney T cell infiltrates.Oncoimmunology · 2022Article
- A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2021Review
- [Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Article
- Adverse events induced by immune checkpoint inhibitors.Current opinion in immunology · 2021Review
- Anti-PD-1-Induced Hidradenitis Suppurativa.Dermatopathology (Basel, Switzerland) · 2021Article
- Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options.Cells · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune check point inhibitor (CPI) therapy has revolutionized treatment paradigms for several cancers, but at the cost of triggering a diverse spectrum of immune-mediated injury to non-cancer tissues. The complex biology of these toxicities remains incompletely understood, partly because tissue acquisition from affected areas can be challenging to retrieve, thus hindering development of targeted therapy. Here, we review the literature describing pathology of immune-mediated tissue lesions including gastrointestinal, skin, rheumatic, pulmonary, cardiac, renal and hepatic lesions and highlight key immunological insights.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.